Prescribed Reading: AZ sell-off, Merck wins ESMO, generics dominate

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 13, 2016

Esperion beefs up late-stage cholesterol program

The drugmaker plans to add patients to its Phase 3 trial, changing the design as it faces an uncertain regulatory environment. 

By Lisa LaMotta • Oct. 13, 2016

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

After setback, Adaptimmune revamps T cell study

No objective responses were seen in an ovarian cancer study, prompting Adaptimunne to modify the pre-conditioning regimen. 

By Suzanne Elvidge • Oct. 13, 2016

Merck KGaA, Pfizer and Transgene team up on cancer vaccine

The French biotech announced collaborations with Merck KGaA and Pfizer to evaluate its HPV-positive head and neck cancer vaccine in combo with avelumab.

By Joe Cantlupe • Oct. 12, 2016

Swiss Auris aims to bounce back from trial miss

Keyzilen, a drug in development for tinnitus, flopped in Phase 2. But Auris believes results seen in two subgroups could help an ongoing Phase 3 study hit its mark. 

By Joe Cantlupe • Oct. 12, 2016

AstraZeneca halts asthma study in blow to Synairgen

Synairgen shares nosedived on news of AstraZeneca's decision, which sets back development of the small biotech's lead candidate. 

By Ned Pagliarulo • Oct. 12, 2016

Supernus readies Phase 3 after positive ADHD data

Shares jumped in initial trading on the news, only to reverse those gains later in the morning. 

By Suzanne Elvidge • Oct. 11, 2016

Exelixis touts kidney cancer drug at ESMO

Strong data in renal cell carcinoma could support Cabometyx as a first-line therapy. 

By Joe Cantlupe • Oct. 11, 2016

Tesaro shakes up PARP battle at ESMO

The biotech reported strong results for niraparib at the medical meeting this weekend, putting it in line for a near-term approval. 

By Joe Cantlupe • Oct. 10, 2016

Novartis' breast cancer drug scores big at ESMO

The Swiss pharma is touting its latest data for ribociclib as it faces off with Pfizer in the closely-watched CDK 4/6 inhibitor class. 

By Joe Cantlupe • Oct. 10, 2016

Bristol bows to Merck in lung cancer

Detailed analysis of Opdivo's lung cancer data hasn't uncovered any silver lining to the first-line failure earlier this year. 

By Suzanne Elvidge • Oct. 10, 2016

Roche stays competitive in I/O race

Tecentriq helped previously treated NSCLC patients live longer compared to standard chemotherapy, regardless of PD-L1 expression. 

By Suzanne Elvidge • Oct. 10, 2016

RedHill adds option for Phase 3 early stop in Crohn's

The biotech is confident an interim analysis next year in its Phase 3 trial will show positive results. 

By Suzanne Elvidge • Oct. 7, 2016

Prescribed Reading: Pharma re-focuses, face-off at ESMO, Hep C boxed

Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week.

By Lisa LaMotta • Oct. 6, 2016

Alnylam abandons RNA drug after patient deaths

While the company said the decision would not affect its other RNAi programs, shares plunged by over 45% on the news. 

By Joe Cantlupe • Oct. 6, 2016

Scynexis buoyed by mid-stage data, new funding

Positive results from two Phase 2 studies bolstered the profile of the company's lead antifungal candidate. 

By Suzanne Elvidge • Oct. 6, 2016

AstraZeneca's Brilinta loses out to old standby

The setback, six months after a failure in a major stroke study, could put a major dent in the company's efforts to grow revenues from the drug. 

By Joe Cantlupe • Oct. 5, 2016

Tracon readies Phase 3 cancer trial

The San Diego-based biopharma plans to begin late-stage testing for its angiosarcoma drug by year end. 

By Suzanne Elvidge • Oct. 4, 2016

Cempra charging ahead in NASH race

The company reported positive Phase 2 interim results for its NASH drug, just as competition to be first to market heats up among other players in the space. 

By Joe Cantlupe • Oct. 3, 2016

Regeneron and Sanofi tout dupilumab success

Data from two Phase 3 studies, published in NEJM over the weekend, show the drug helped clear symptoms of patients with severe eczema. 

By Suzanne Elvidge • Oct. 3, 2016

J&J's psoriasis drug trumps Humira in Phase 3

Janssen is testing its IL-23 inhibitor guselkumab in two other Phase 3 studies, hoping to build on the success of Stelara and the rest of its psoriasis portfolio. 

By Suzanne Elvidge • Oct. 3, 2016

Alnylam shifts gears after safety issues

Alnylam said Thursday it halted continuation of proposed liver disease drug RNAi based on safety concerns in a Phase 1-2 study, and will pursue regulatory approval for another therapy. 

By Joe Cantlupe • Sept. 30, 2016

UPDATED: BI plays hot potato with Hanmi, returns cancer drug

The German drugmaker abruptly abandoned a mid-stage lung cancer drug after reports surfaced about patient deaths. 

By Lisa LaMotta • Sept. 30, 2016

Regeneron slips on trial setback for Eylea combo

Pairing Eylea with an experimental antibody led to poorer safety and efficacy data in wet AMD patients than treatment with Eylea alone.  

By Ned Pagliarulo • Sept. 30, 2016

FDA halts trial of Alcobra's ADHD drug

Alcobra said the FDA verbally issued a full clinical hold due to concerns over preclinical neurological data. 

By Suzanne Elvidge • Sept. 30, 2016